Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $40.00 by Analysts at HC Wainwright

Jasper Therapeutics (NASDAQ:JSPR) had its price objective trimmed by HC Wainwright from $60.00 to $40.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Jasper Therapeutics’ FY2029 earnings at ($10.81) EPS.

Other equities analysts have also recently issued reports about the company. Royal Bank of Canada reduced their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday. JMP Securities restated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. Finally, BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price for the company. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR opened at $7.05 on Friday. The company has a market cap of $105.76 million, a price-to-earnings ratio of -1.49 and a beta of 2.18. Jasper Therapeutics has a one year low of $6.57 and a one year high of $31.01. The firm has a fifty day moving average price of $21.37 and a two-hundred day moving average price of $20.27.

Hedge Funds Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp purchased a new stake in Jasper Therapeutics during the second quarter valued at about $740,000. Rhumbline Advisers purchased a new stake in Jasper Therapeutics during the 2nd quarter valued at about $300,000. American Century Companies Inc. grew its position in Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after acquiring an additional 3,032 shares during the last quarter. Wolff Wiese Magana LLC bought a new stake in Jasper Therapeutics in the third quarter valued at approximately $59,000. Finally, Fernwood Investment Management LLC boosted its stake in shares of Jasper Therapeutics by 6.9% during the third quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after purchasing an additional 3,427 shares during the period. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.